Kiora Pharmaceuticals (KPRX)
Develops intravitreal photoswitch and DHODH-inhibitor candidates for retinal degeneration and inflammation.
Something off on this page? Send us feedback.
Develops intravitreal small-molecule candidates for inherited retinal degeneration and retinal inflammation. Relies on license-related payments, partner reimbursements, potential milestones, and royalties rather than product sales.
Develops KIO-301, an intravitreal molecular photoswitch intended to make surviving retinal ganglion cells light-responsive after photoreceptor loss, and KIO-104, an intravitreal DHODH inhibitor for retinal inflammation and macular edema. Both candidates are in mid-stage clinical studies.
Operates from Encinitas and through offices and trial sites in Australia and Austria, while reporting one geographic segment. Its asset- and partnership-oriented model uses acquired technologies, outsources clinical work and manufacturing, and has licensed most non-Asian ophthalmic rights to KIO-301 to Théa Open Innovation.
Has no approved products or product sales. Its economics depend on upfront and option payments, reimbursed research costs, potential milestones, and royalties, while clinical execution depends on third-party manufacturers, CROs, medical institutions, investigators, and data-management providers.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $16.8M · Total debt $333.0K · Total assets $23.8M · Shareholders' equity $16.9M
- Revenue
- $0
- Operating income
- −$2.2M
- Net income
- −$2.1M
No dividends on record.
| Insiders | 2.64% | 116.7K shares | |
|---|---|---|---|
| 4 holders · as of Jul 2, 2026 | |||
| Strategic holders | 18.70% | 827.2K shares | |
| 2 holders · as of Feb 11, 2026 | |||
| Other | 78.66% | 3.48M shares | |
| remainder | |||
4.42M company shares as of Sep 22, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Rosalind Advisors, Inc.Strategic | 10.50% | 464,676 | filed Feb 11, 2026 |
Perceptive Advisors LLCInstitution | 10.00% | 442,387 | filed Aug 10, 2026 |
Nantahala Capital Management, LLCInstitution | 9.91% | 438,469 | filed May 15, 2026 |
Alyeska Investment Group, L.P.Institution | 8.92% | 394,668 | filed May 15, 2026 |
ADAR1 Capital Management, LLCStrategic | 8.19% | 362,527 | filed Aug 14, 2025 |
Insider tradesForm 4
No open-market trades in the last 12 months.
